Vaccinex sees long term value in building clinical programs that beneficially impact patient care. With that goal in mind, we are building a pipeline of novel candidate therapeutics that we hope will improve upon existing therapies and offer patient treatment options that improve their quality of life. Use the menu on the left to browse our clinical programs.

 

Product pipeline:

 

Active Clinical Trials

June – 2015 – Huntington’s Disease SIGNAL trial

A Phase 2, multi-center, randomized, double-blinded, placebo-controlled clinical trial in subjects with late prodromal and early manifest Huntington disease (HD) to assess safety, tolerability, pharmacokinetics, and efficacy of VX15/2503

 

Link to clinicaltrials.gov page for this study
Flyer with more information

 

February – 2018 – Vaccinex Sponsored a Key Opinion Leader (KOL) Luncheon on Huntington’s Disease

A Key Opinion Leader (KOL) Luncheon on Huntington’s Disease (HD) was hosted by Vaccinex on February 6, 2018.  The meetings featured presentations by Ira Shoulson, MD, (Georgetown University), Karl Kieburtz, MD, MPH (University of Rochester), and Maurice Zauderer, Ph.D. (Vaccinex, Inc.) who provided an update on the Company’s SIGNAL trial (Phase 2 study of investigational VX15/2503 antibody in HD). Discussion included recent research and the current treatment landscape, as well as the unmet medical need for treating patients with Huntington’s Disease.

 

To see and hear a replay of the KOL Luncheon, please click here to register or log in.

 

VX15/2503 in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer (CLASSICAL-Lung)
Phase 1b/2 Study of VX15/2503 in combination with avelumab in non-small cell lung cancer

 

Link to clinicaltrials.gov page for this study
Link to press release

 

Additional clinical trials involving pepinemab (VX15/2503):

Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients with Stage III or IV Melanoma
Phase I Study of Combining an Anti-SEMA4D Antibody VX15/2503 with Checkpoint Inhibitors for Patients with Advanced Melanoma Who Have Progressed on Prior Anti-PD1/L1 Based Therapies

 

Sponsor:
Jonsson Comprehensive Cancer Center (UCLA)

Collaborator:
National Cancer Institute (NCI)

This randomized pilot phase I trial studies the side effects and best dose of anti-SEMA4D monoclonal antibody VX15/2503 when given together with nivolumab or ipilimumab in treating patients with stage III or IV melanoma. Monoclonal antibodies, such as anti-SEMA4D monoclonal antibody VX15/2503, nivolumab, and ipilimumab, may interfere with the ability of tumor cells to grow and spread.

 

Link to clinicaltrials.gov page for this study

 

VX15/2503 in Treating Younger Patients with Recurrent, Relapsed, or Refractory Solid Tumors
A Phase 1/2 Trial of VX15/2503, a Humanized Monoclonal Antibody to Semaphorin 4D, in Pediatric patients with Relapsed or Refractory Solid Tumors

 

Sponsor:
Children’s Oncology Group

Collaborator:
National Cancer Institute (NCI)

This phase I/II trial studies the side effects and best dose of anti-SEMA4D monoclonal antibody VX15/2503 (VX15/2503) and to see how well it works in treating younger patients with solid tumors that have come back after prior treatment, or did not respond to prior treatment. Monoclonal antibodies, such as VX15/2503, may interfere with the ability of tumor cells to grow and spread.

 

Link to clinicaltrials.gov page for this study
Link to press release

 

VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer
Phase I Integrated Biomarker Trial of VX15/2503 in Combination with Ipilimumab or Nivolumab as Neoadjuvant Treatment in Patients with Pancreatic and Colorectal Cancer

 

Sponsor:
Emory University

Collaborator:
Vaccinex Inc.

This randomized phase I trial studies how well anti-SEMA4D monoclonal antibody VX15/2503 in combination with or without ipilimumab or nivolumab affects tumor in patients with stage I-III pancreatic cancer that can be removed by surgery or stage IV colorectal cancer that has spread to the liver and can be removed by surgery. Monoclonal antibodies, such as anti-SEMA4D monoclonal antibody VX15/2503, ipilimumab, and nivolumab, may interfere with the ability of tumor cells to grow and spread.

 

Link to clinicaltrials.gov page for this study